Acrodermatitis continua of Hallopeau with insufficient response to ixekizumab and infliximab, successfully treated with a combination of ustekinumab and tofacitinib
Eur J Dermatol
.
2023 Apr 1;33(2):182-183.
doi: 10.1684/ejd.2023.4461.
Authors
Xiaohong Chen
1
,
Xiaoyan Huang
2
,
Li Ma
1
,
Bin Wang
1
,
Jiabin Tian
1
,
Xiaoming Liu
1
Affiliations
1
Department of Dermatology, The University of Hong Kong Shenz hen Hospital, Shenzhen, China 518053.
2
Department of Rheumatology, The University of Hong Kong Shenzhen Hospital, Shenzhen, China 518053.
PMID:
37431132
DOI:
10.1684/ejd.2023.4461
No abstract available
MeSH terms
Acrodermatitis* / drug therapy
Exanthema*
Humans
Infliximab / therapeutic use
Ustekinumab
Substances
ixekizumab
Ustekinumab
tofacitinib
Infliximab